LPTX - Leap Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
0.62 -0.01 (-1.21%)	---	-0.01 (-1.15%)	0.0 (-0.07%)	0.0 (0.16%)	-0.01 (-1.84%)	0.0 (0.13%)	0.0 (0.13%)

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.4
Diluted EPS:: -0.4
Basic P/E:: -1.531
Diluted P/E:: -1.531
RSI(14) 1m:: 49.67
VWAP:: 0.61
RVol:: 0.1109

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	0.61 -0.01 (-1.98%)	Oct 15 18:04
1m	Price increase 1m	0.62 +0.01 (+1.09%)	Oct 15 15:54
1m	Price decrease 1m	0.61 -0.01 (-1.95%)	Oct 15 15:53
1m	Price decrease 1m	0.61 -0.01 (-1.35%)	Oct 15 15:33
1m	Price increase 1m	0.63 +0.01 (+1.57%)	Oct 15 14:01